Wednesday, November 18, 2026

FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia - Pharmaceutical Executive

FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia  Pharmaceutical Executive

NewsKrez Editorial DeskNovember 16, 2026 • 11:45 AM UTC
3 min read2 views
FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia - Pharmaceutical Executive
Source: Google News Regulatory & Pharma Intelligence
FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated with Schizophrenia  Pharmaceutical Executive
Regulatory Verification & Source Attribution

This intelligence report was compiled and verified by the NewsKrez Editorial & Regulatory Intelligence Desk.

Sponsored Intelligence
Medical Device Software Compliance

Automated 21 CFR Part 820 & ISO 13485 Verification

Explore Solution →